Budesonide in the first line treatment of patients with autoimmune hepatitis

Lohse, 2015, EASL clinical practice guidelines: autoimmune hepatitis, J Hepatol, 63, 971, 10.1016/j.jhep.2015.06.030 Mieli-Vergani, 2018, Autoimmune hepatitis, Nat Rev Dis Prim, 4 Mack, 2020, Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases, Hepatology, 72, 671, 10.1002/hep.31065 De Martin, 2021, Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score, J Hepatol, 74, 1325, 10.1016/j.jhep.2020.12.033 Williams, 2018, Clinical pharmacology of corticosteroids, Respir Care, 63, 655, 10.4187/respcare.06314 Czock, 2005, Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids, Clin Pharmacokinet, 44, 61, 10.2165/00003088-200544010-00003 He, 2014, Structures and mechanism for the design of highly potent glucocorticoids, Cell Res, 24, 713, 10.1038/cr.2014.52 Hamedani, 1997, Review article: drug development in inflammatory bowel disease: budesonide – a model of targeted therapy, Aliment Pharmacol Ther Suppl, 11, 98, 10.1111/j.1365-2036.1997.tb00814.x Adcock, 2016, Glucocorticoids, Handb Exp Pharmacol, 237, 171, 10.1007/164_2016_98 Meikle, 1977, Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary–adrenal function, Am J Med, 63, 200, 10.1016/0002-9343(77)90233-9 Greenberg, 1994, Oral budesonide for active Crohn's disease, N Engl J Med, 331, 836, 10.1056/NEJM199409293311303 Kalola, 2021, Budesonide, xPharm Compr Pharmacol Ref, 1 Brattsand, 1990, Overview of newer glucocorticosteroid preparations for inflammatory bowel disease, Can J Gastroenterol, 4, 407, 10.1155/1990/708916 Manns, 2010, Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis, Gastroenterology, 139, 1198, 10.1053/j.gastro.2010.06.046 Geier, 2003, Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC, World J Gastroenterol, 9, 2681, 10.3748/wjg.v9.i12.2681 Ficha Técnica Budesonida 3 MG. Agencia Española Medicam y Prod Sanit; 2019. Danielsson, 1994, Oral budesonide for treatment of autoimmune chronic active hepatitis, Aliment Pharmacol Ther, 8, 585, 10.1111/j.1365-2036.1994.tb00334.x Wiegand, 2005, Budesonide in previously untreated autoimmune hepatitis, Liver Int, 25, 927, 10.1111/j.1478-3231.2005.01122.x Woynarowski, 2013, Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents, J Pediatr, 163 Delgado, 2013, Autoimmune hepatitis in southern Israel: a 15-year multicenter study, J Dig Dis, 14, 611, 10.1111/1751-2980.12085 Binicier ÖB, 2019, The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study, Croat Med J, 60, 345, 10.3325/cmj.2019.60.345 van den Brand, 2019, Adverse events related to low dose corticosteroids in autoimmune hepatitis, Aliment Pharmacol Ther, 50, 1120, 10.1111/apt.15528 Dyson, 2018, Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom, 48, 951 Á. Díaz-González, 2021, Eficacia y seguridad de la budesonida como primera línea de tratamiento en pacientes con hepatitis autoinmune: Estudio multicéntrico español, Congr Anu Asoc Española para el Estud del Hígado Efe, 2012, Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome, Autoimmun Rev, 11, 330, 10.1016/j.autrev.2011.09.006 Hirschfield, 2021, A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA, J Hepatol, 74, 321, 10.1016/j.jhep.2020.09.011 De Maeyer, 2018, Secondary adrenal insufficiency after treatment with budesonide for autoimmune hepatitis, Case Rep Gastroenterol, 12, 597, 10.1159/000492204 Suzuki, 2013, Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study, J Crohn's Colitis, 7, 239, 10.1016/j.crohns.2012.06.006 Hanauer, 2005, Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial, Aliment Pharmacol Ther, 21, 363, 10.1111/j.1365-2036.2005.02338.x Münch, 2016, Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial, Gut, 65, 47, 10.1136/gutjnl-2014-308363 Miehlke, 2018, Oral budesonide in gastrointestinal and liver disease: a practical guide for the clinician, J Gastroenterol Hepatol, 33, 1574, 10.1111/jgh.14151 López-Sanromán, 2018, Reviewing the therapeutic role of budesonide in Crohn's disease, Gastroenterol Hepatol, 41, 458, 10.1016/j.gastrohep.2018.05.013 Schoon, 2005, Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease, Clin Gastroenterol Hepatol, 3, 113, 10.1016/S1542-3565(04)00662-7 Cino, 2002, Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy, Am J Gastroenterol, 97, 915, 10.1111/j.1572-0241.2002.05609.x Soloway, 1972, Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis, Gastroenterology., 63, 820, 10.1016/S0016-5085(19)33223-8 Murray-Lyon, 1973, Controlled trial of prednisone and azathioprine in active chronic hepatitis, Lancet., 301, 735, 10.1016/S0140-6736(73)92125-9 Summerskill, 1975, Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared, Gut., 16, 876, 10.1136/gut.16.11.876 Tage-Jensen, 1982, Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD), Relation to a serological classification. Liver., 2, 95 Lamers, 2010, Treatment options for autoimmune hepatitis: A systematic review of randomized controlled trials, J Hepatol., 53, 191, 10.1016/j.jhep.2010.01.037 Csepregi, 2006, Budesonide induces complete remission in autoimmune hepatitis, World J Gastroenterol., 12, 1362, 10.3748/wjg.v12.i9.1362 Mieli-Vergani, 2018, Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement, J Pediatr Gastroenterol Nutr., 66, 345, 10.1097/MPG.0000000000001801 Dalekos, 2019, Hellenic association for the study of the liver clinical practice guidelines: Autoimmune hepatitis, Ann Gastroenterol., 32, 1 Gleeson, 2011, British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis, Gut., 60, 1611, 10.1136/gut.2010.235259